Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 9/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5579013 | 0.85 | PTPN2 (0.59) | PTPN2PTPN1PTPN6NPC1RAB9A | |
| SCHEMBL3171133 | 0.84 | PTPN2 (0.58) | PTPN2PTPN1PTPN6NPC1RAB9A | |
| SCHEMBL860245 | 0.83 | PTPN2 (0.57) | PTPN2PTPN1PTPN6NPC1RAB9A | |
| SCHEMBL3171666 | 0.82 | STS (0.56) | PTPN2PTPN1PTPN6NPC1RAB9A | |
| SCHEMBL3186189 | 0.82 | PTPN2 (0.56) | PTPN2PTPN1PTPN6NPC1RAB9A | |
| SCHEMBL2108811 | 0.81 | PTPN2 (0.55) | PTPN2PTPN1PTPN6NPC1RAB9A | |
| SCHEMBL3181308 | 0.81 | PTPN2 (0.62) | PTPN2PTPN1PTPN6NPC1RAB9A | |
| SCHEMBL841859 | 0.80 | PTPN2 (0.54) | PTPN2PTPN1PTPN6NPC1RAB9A | |
| SCHEMBL26664390 | 0.79 | PTPN2 (0.60) | PTPN2PTPN1PTPN6NPC1RAB9A | |
| SCHEMBL3177867 | 0.77 | STS (0.60) | PTPN2PTPN1PTPN6NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536189-B2 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | COSTANZO MICHAEL J (US) | 2012-06-28 | — | — | US | disclosed |
| US-8158792-B2 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| US-20090163527-A1 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | PTPN2 1772/4885PTPN1 1535/4885PTPN6 1665/4885 |
| US-20090163527-A1 | Spiropiperidines for use as tryptase inhibitors | TPSAB1, TPSB2, TPSD1 | PTPN2 1772/4885PTPN1 1535/4885PTPN6 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.